Dianthus Therapeutics, Inc. (DNTH)

Market Cap	2.30B +232.0%
Revenue (ttm)	3.08M -42.6%
Net Income	-126.35M
EPS	-3.49
Shares Out	43.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	970,018
Open	51.25
Previous Close	51.87
Day's Range	51.00 - 54.00
52-Week Range	13.37 - 57.50
Beta	1.23
Analysts	Strong Buy
Price Target	71.22 (+34.1%)
Earnings Date	Mar 11, 2026

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: DNTH
• Website: https://dianthustx.com

Financial Performance

In 2024, Dianthus Therapeutics's revenue was $6.24 million, an increase of 120.63% compared to the previous year's $2.83 million. Losses were -$84.97 million, 95.1% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $71.22, which is an increase of 34.10% from the latest price.

Price Target

$71.22

(34.10% upside)

Analyst Consensus: Strong Buy